Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis
In colorectal cancer, whereas mucinous adenocarcinoma (MAC) has several poor clinical prognostic factors compared to adenocarcinoma (AC), the prognosis of MAC remains controversial. We evaluated the prognosis of MAC without distant metastasis and the effects of adjuvant chemotherapy using health ins...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-03, Vol.14 (5), p.1297 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1297 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Bong, Jun-Woo Gim, Jeong-An Ju, Yeonuk Cheong, Chinock Lee, Sun-Il Oh, Sang-Cheul Min, Byung-Wook Kang, Sanghee |
| description | In colorectal cancer, whereas mucinous adenocarcinoma (MAC) has several poor clinical prognostic factors compared to adenocarcinoma (AC), the prognosis of MAC remains controversial. We evaluated the prognosis of MAC without distant metastasis and the effects of adjuvant chemotherapy using health insurance registry data managed by South Korea. Patients with colorectal cancer between January 2014 and December 2016 were included (AC, 22,050 [96.8%]; MAC, 729 [3.2%]). We observed no difference in overall survival (OS) between AC and MAC in stages I and II. However, MAC showed a worse OS than AC in stage III disease, especially in patients administered chemotherapy (p < 0.001). These findings persisted after propensity score matching of clinical characteristics between AC and MAC. In addition, transcriptome analysis of The Cancer Genome Atlas (TCGA) data showed increased chemoresistance-associated pathways in MAC compared to AC. In consensus molecular subtypes (CMS) classification, unlike in AC, CMSs 1, 3, and 4 comprised most of MAC and the proportions of CMSs 3 and 4 increased with stage progression. These results suggest clues to overcome resistance to chemotherapy and develop targeted treatments in MAC. |
| doi_str_mv | 10.3390/cancers14051297 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8909839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638723047</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-dd0b9087e976d6a157333c2a29dbf155bd2783b1eedd681ce6f04d1d6e4620de3</originalsourceid><addsrcrecordid>eNpdkc9LHDEUx0NpqWI99yaBXnpZzY-ZZHIRZLVWUFpoew6Z5I2bZSbZJpmV_e-bRSvqu-TB-7zvy5cvQp8pOeVckTNrgoWUaUNaypR8hw4ZkWwhhGrev-gP0HHOa1KLcyqF_IgOeMuEFKQ9RPlnivchZp-xCQ7_gpB98VtfdjgO-MKt560JBS9XMMWygmQ2O-wDvputD3HOeBnHmMAWM1YYQrQm7SeTwQ--rOJc8KXPZS9xB8XUrl76hD4MZsxw_PQeoT_frn4vvy9uf1zfLC9uF7ZhtCycI70inQQlhROGtpJzbplhyvUDbdveMdnxngI4JzpqQQykcdQJaAQjDvgROn_U3cz9BM5CKMmMepP8ZNJOR-P160nwK30ft7pTRHVcVYGvTwIp_p0hFz35bGEcTYBqXjPBO8k4aWRFv7xB13FOodrbU1LQrmFdpc4eKZtizgmG589QoveZ6jeZ1o2Tlx6e-f8J8n_MXKGb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637618428</pqid></control><display><type>article</type><title>Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Bong, Jun-Woo ; Gim, Jeong-An ; Ju, Yeonuk ; Cheong, Chinock ; Lee, Sun-Il ; Oh, Sang-Cheul ; Min, Byung-Wook ; Kang, Sanghee</creator><creatorcontrib>Bong, Jun-Woo ; Gim, Jeong-An ; Ju, Yeonuk ; Cheong, Chinock ; Lee, Sun-Il ; Oh, Sang-Cheul ; Min, Byung-Wook ; Kang, Sanghee</creatorcontrib><description>In colorectal cancer, whereas mucinous adenocarcinoma (MAC) has several poor clinical prognostic factors compared to adenocarcinoma (AC), the prognosis of MAC remains controversial. We evaluated the prognosis of MAC without distant metastasis and the effects of adjuvant chemotherapy using health insurance registry data managed by South Korea. Patients with colorectal cancer between January 2014 and December 2016 were included (AC, 22,050 [96.8%]; MAC, 729 [3.2%]). We observed no difference in overall survival (OS) between AC and MAC in stages I and II. However, MAC showed a worse OS than AC in stage III disease, especially in patients administered chemotherapy (p < 0.001). These findings persisted after propensity score matching of clinical characteristics between AC and MAC. In addition, transcriptome analysis of The Cancer Genome Atlas (TCGA) data showed increased chemoresistance-associated pathways in MAC compared to AC. In consensus molecular subtypes (CMS) classification, unlike in AC, CMSs 1, 3, and 4 comprised most of MAC and the proportions of CMSs 3 and 4 increased with stage progression. These results suggest clues to overcome resistance to chemotherapy and develop targeted treatments in MAC.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14051297</identifier><identifier>PMID: 35267605</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Body mass index ; Chemoresistance ; Chemotherapy ; Classification ; Colorectal cancer ; Colorectal carcinoma ; Disease ; Gene expression ; Genomes ; Lymphatic system ; Medical prognosis ; Mesenchyme ; Metastases ; Metastasis ; Mortality ; Multivariate analysis ; Patients ; Prognosis ; Surgery ; Survival ; Survival analysis ; Transcriptomes</subject><ispartof>Cancers, 2022-03, Vol.14 (5), p.1297</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-dd0b9087e976d6a157333c2a29dbf155bd2783b1eedd681ce6f04d1d6e4620de3</citedby><cites>FETCH-LOGICAL-c421t-dd0b9087e976d6a157333c2a29dbf155bd2783b1eedd681ce6f04d1d6e4620de3</cites><orcidid>0000-0002-9530-7069 ; 0000-0002-6097-8831</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909839/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909839/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27926,27927,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35267605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bong, Jun-Woo</creatorcontrib><creatorcontrib>Gim, Jeong-An</creatorcontrib><creatorcontrib>Ju, Yeonuk</creatorcontrib><creatorcontrib>Cheong, Chinock</creatorcontrib><creatorcontrib>Lee, Sun-Il</creatorcontrib><creatorcontrib>Oh, Sang-Cheul</creatorcontrib><creatorcontrib>Min, Byung-Wook</creatorcontrib><creatorcontrib>Kang, Sanghee</creatorcontrib><title>Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>In colorectal cancer, whereas mucinous adenocarcinoma (MAC) has several poor clinical prognostic factors compared to adenocarcinoma (AC), the prognosis of MAC remains controversial. We evaluated the prognosis of MAC without distant metastasis and the effects of adjuvant chemotherapy using health insurance registry data managed by South Korea. Patients with colorectal cancer between January 2014 and December 2016 were included (AC, 22,050 [96.8%]; MAC, 729 [3.2%]). We observed no difference in overall survival (OS) between AC and MAC in stages I and II. However, MAC showed a worse OS than AC in stage III disease, especially in patients administered chemotherapy (p < 0.001). These findings persisted after propensity score matching of clinical characteristics between AC and MAC. In addition, transcriptome analysis of The Cancer Genome Atlas (TCGA) data showed increased chemoresistance-associated pathways in MAC compared to AC. In consensus molecular subtypes (CMS) classification, unlike in AC, CMSs 1, 3, and 4 comprised most of MAC and the proportions of CMSs 3 and 4 increased with stage progression. These results suggest clues to overcome resistance to chemotherapy and develop targeted treatments in MAC.</description><subject>Adenocarcinoma</subject><subject>Body mass index</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>Classification</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Disease</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Transcriptomes</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc9LHDEUx0NpqWI99yaBXnpZzY-ZZHIRZLVWUFpoew6Z5I2bZSbZJpmV_e-bRSvqu-TB-7zvy5cvQp8pOeVckTNrgoWUaUNaypR8hw4ZkWwhhGrev-gP0HHOa1KLcyqF_IgOeMuEFKQ9RPlnivchZp-xCQ7_gpB98VtfdjgO-MKt560JBS9XMMWygmQ2O-wDvputD3HOeBnHmMAWM1YYQrQm7SeTwQ--rOJc8KXPZS9xB8XUrl76hD4MZsxw_PQeoT_frn4vvy9uf1zfLC9uF7ZhtCycI70inQQlhROGtpJzbplhyvUDbdveMdnxngI4JzpqQQykcdQJaAQjDvgROn_U3cz9BM5CKMmMepP8ZNJOR-P160nwK30ft7pTRHVcVYGvTwIp_p0hFz35bGEcTYBqXjPBO8k4aWRFv7xB13FOodrbU1LQrmFdpc4eKZtizgmG589QoveZ6jeZ1o2Tlx6e-f8J8n_MXKGb</recordid><startdate>20220302</startdate><enddate>20220302</enddate><creator>Bong, Jun-Woo</creator><creator>Gim, Jeong-An</creator><creator>Ju, Yeonuk</creator><creator>Cheong, Chinock</creator><creator>Lee, Sun-Il</creator><creator>Oh, Sang-Cheul</creator><creator>Min, Byung-Wook</creator><creator>Kang, Sanghee</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9530-7069</orcidid><orcidid>https://orcid.org/0000-0002-6097-8831</orcidid></search><sort><creationdate>20220302</creationdate><title>Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis</title><author>Bong, Jun-Woo ; Gim, Jeong-An ; Ju, Yeonuk ; Cheong, Chinock ; Lee, Sun-Il ; Oh, Sang-Cheul ; Min, Byung-Wook ; Kang, Sanghee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-dd0b9087e976d6a157333c2a29dbf155bd2783b1eedd681ce6f04d1d6e4620de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma</topic><topic>Body mass index</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>Classification</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Disease</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Transcriptomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bong, Jun-Woo</creatorcontrib><creatorcontrib>Gim, Jeong-An</creatorcontrib><creatorcontrib>Ju, Yeonuk</creatorcontrib><creatorcontrib>Cheong, Chinock</creatorcontrib><creatorcontrib>Lee, Sun-Il</creatorcontrib><creatorcontrib>Oh, Sang-Cheul</creatorcontrib><creatorcontrib>Min, Byung-Wook</creatorcontrib><creatorcontrib>Kang, Sanghee</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bong, Jun-Woo</au><au>Gim, Jeong-An</au><au>Ju, Yeonuk</au><au>Cheong, Chinock</au><au>Lee, Sun-Il</au><au>Oh, Sang-Cheul</au><au>Min, Byung-Wook</au><au>Kang, Sanghee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-03-02</date><risdate>2022</risdate><volume>14</volume><issue>5</issue><spage>1297</spage><pages>1297-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>In colorectal cancer, whereas mucinous adenocarcinoma (MAC) has several poor clinical prognostic factors compared to adenocarcinoma (AC), the prognosis of MAC remains controversial. We evaluated the prognosis of MAC without distant metastasis and the effects of adjuvant chemotherapy using health insurance registry data managed by South Korea. Patients with colorectal cancer between January 2014 and December 2016 were included (AC, 22,050 [96.8%]; MAC, 729 [3.2%]). We observed no difference in overall survival (OS) between AC and MAC in stages I and II. However, MAC showed a worse OS than AC in stage III disease, especially in patients administered chemotherapy (p < 0.001). These findings persisted after propensity score matching of clinical characteristics between AC and MAC. In addition, transcriptome analysis of The Cancer Genome Atlas (TCGA) data showed increased chemoresistance-associated pathways in MAC compared to AC. In consensus molecular subtypes (CMS) classification, unlike in AC, CMSs 1, 3, and 4 comprised most of MAC and the proportions of CMSs 3 and 4 increased with stage progression. These results suggest clues to overcome resistance to chemotherapy and develop targeted treatments in MAC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35267605</pmid><doi>10.3390/cancers14051297</doi><orcidid>https://orcid.org/0000-0002-9530-7069</orcidid><orcidid>https://orcid.org/0000-0002-6097-8831</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-03, Vol.14 (5), p.1297 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8909839 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB Electronic Journals Library |
| subjects | Adenocarcinoma Body mass index Chemoresistance Chemotherapy Classification Colorectal cancer Colorectal carcinoma Disease Gene expression Genomes Lymphatic system Medical prognosis Mesenchyme Metastases Metastasis Mortality Multivariate analysis Patients Prognosis Surgery Survival Survival analysis Transcriptomes |
| title | Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T16%3A48%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20and%20Sensitivity%20of%20Adjuvant%20Chemotherapy%20in%20Mucinous%20Colorectal%20Adenocarcinoma%20without%20Distant%20Metastasis&rft.jtitle=Cancers&rft.au=Bong,%20Jun-Woo&rft.date=2022-03-02&rft.volume=14&rft.issue=5&rft.spage=1297&rft.pages=1297-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14051297&rft_dat=%3Cproquest_pubme%3E2638723047%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637618428&rft_id=info:pmid/35267605&rfr_iscdi=true |